Pasithea Therapeutics (KTTA) Receivables (2022 - 2025)
Pasithea Therapeutics recorded quarterly Receivables of $43000.0 in Q4 2025, little changed quarter-over-quarter from $43000.0 in Q1 2025.
Pasithea Therapeutics' Receivables history runs 2 years deep, the most recent figure standing at $43000.0 for Q4 2025.
- In Q4 2025, Receivables changed N/A year-over-year to $43000.0; the TTM figure through Dec 2025 stood at $43000.0 (changed N/A YoY), while the FY2025 annual figure was $43000.0, changed N/A from the prior year.
- Receivables came in at $43000.0 for Q4 2025 at Pasithea Therapeutics, roughly flat from $43000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $200000.0 in Q4 2022 to a low of $43000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43,000.00 |
| Dec 31, 2022 | 200,000.00 |